Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report)'s share price gapped up prior to trading on Wednesday . The stock had previously closed at $8.50, but opened at $8.93. Ginkgo Bioworks shares last traded at $9.14, with a volume of 287,788 shares changing hands.
Ginkgo Bioworks Stock Performance
The stock has a market capitalization of $542.59 million, a price-to-earnings ratio of -0.71 and a beta of 1.25. The business has a fifty day simple moving average of $7.49 and a 200 day simple moving average of $9.06.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.35). The firm had revenue of $48.32 million for the quarter, compared to analyst estimates of $38.70 million. Ginkgo Bioworks had a negative return on equity of 58.54% and a negative net margin of 298.78%. On average, sell-side analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Palumbo Wealth Management LLC bought a new stake in Ginkgo Bioworks in the fourth quarter valued at $144,000. Y Intercept Hong Kong Ltd bought a new position in shares of Ginkgo Bioworks during the 4th quarter worth about $154,000. Bank of New York Mellon Corp raised its stake in Ginkgo Bioworks by 48.2% during the 4th quarter. Bank of New York Mellon Corp now owns 23,061 shares of the company's stock worth $226,000 after buying an additional 7,503 shares during the period. SVB Wealth LLC bought a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $171,000. Finally, SBI Securities Co. Ltd. bought a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $29,000. 78.63% of the stock is owned by institutional investors and hedge funds.
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Stories
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
